Procter & Gamble Health Limited (PGHL) fundamentals
Procter & Gamble Health Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as PGHL (ISIN INE199A01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Procter & Gamble Health Limited does
Procter & Gamble Health Limited is an India-based multinational consumer goods company. The Company is focused on manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company is engaged in the manufacturing and selling of healthcare products, such as vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct and indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. The Company’s brands include Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Seven Seas is a pure vitamin rich cod-liver oil. Neurobion offers a range of neurotropic supplements. Its products are sold in about 180 countries and territories throughout the world.
Valuation and market data
| Last close | ₹5411.50 |
|---|---|
| Market capitalisation | ₹8,997 crore |
| Enterprise value | ₹8,861 crore |
| P/E (TTM) | 0.00 |
| Price to book | 16.75 |
| Price to sales (TTM) | 6.20 |
| Book value per share | ₹322.98 |
| Dividend yield | 378.82% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Apr 24 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,425 crore | ₹450 crore | ₹327 crore | 0.00 |
| Mar 2025 | ₹945 crore | ₹312 crore | ₹234 crore | 141.00 |
| Jun 2024 | ₹1,167 crore | ₹273 crore | ₹201 crore | 121.00 |
| Jun 2023 | ₹1,248 crore | ₹314 crore | ₹229 crore | 138.00 |
| Jun 2022 | ₹1,128 crore | ₹253 crore | ₹193 crore | 116.00 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 51.8% |
|---|---|
| Foreign institutions (FII) | 6.3% |
| Mutual funds | 9.1% |
| Other domestic institutions | 3.4% |
| Retail and others | 29.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.